Table 2.
STING agonists involving in clinical development
| Agents | molecular types | Route | With or without combinational agents | Targeting cancers | Phase | Clinical Trial NCT Code |
|---|---|---|---|---|---|---|
|
ADU-S100 /MIW815 |
CDN analog | IT | alone or + Ipilimumab | Advanced/metastatic solid tumors or lymphomas | Phase 1 | NCT02675439 |
| IT | +PDR001 | Advanced/metastatic solid tumors or lymphomas | Phase 1/1b | NCT03172936 | ||
| IT | +Pembrolizumab | HNSCC | Phase 2 | NCT03937141 | ||
| BMS-986,301 | CDN analog |
IV/IT/ IM |
Alone or+ Nivolumab and Ipilimumab | Advanced solid tumors | Phase 1 | NCT03956680 |
| BI-1,387,446 | CDN analog | IT | Alone or + Ezabenlimab | Advanced/metastatic solid tumors | Phase 1 | NCT04147234 |
| IMSA-101 | CDN analog | IT | Alone or + ICI/+IO | Advanced solid tumors or lymphomas | Phase 1/2 | NCT04020185 |
| IT | +PULSAR, Pembrolizumab and Nivolumab | NSCLC and RCC | Phase 2 | NCT05846646 | ||
| IT | +PULSAR, Pembrolizumab and Nivolumab | Oligoprogressive solid tumors | Phase 2 | NCT05846659 | ||
| MK-1454 | CDN analog | IT | + Alone or Pembrolizumab | Advanced/metastatic solid tumors or lymphomas | Phase 1 | NCT03010176 |
| IT | +Pembrolizumab | Metastatic or unresectable, recurrent HNSCC | Phase 2 | NCT04220866 | ||
| SB11285 | CDN analog | IV | Alone or + Atezolizumab | Advanced solid tumors | Phase 1 | NCT04096638 |
| TAK-676 | CDN analog | IV | + Pembrolizumab | NSCLC, TNBC and HNSCC | Phase 1 | NCT04879849 |
| IV | Alone or + Pembrolizumab | Advanced/metastatic solid tumors | Phase 1 | NCT04420884 | ||
| E7766 | non-CDN molecule | IT | Alone | NMIBC | Phase 1/1b | NCT04109092 |
| IT | Alone | Advanced/metastatic solid tumors or lymphomas | Phase 1/1b | NCT04144140 | ||
| GSK3745417 | non-CDN molecule | IV | Alone | AML and HR-MDS | Phase 1 | NCT05424380 |
| IV | Alone or + Dostarlimab | Advanced solid tumors | Phase 1 | NCT03843359 | ||
| HG-381 | non-CDN molecule | IV | Alone | Advanced solid tumors | Phase 1 | NCT04998422 |
| KL340399 | non-CDN molecule | IT | Alone | Advanced solid tumors | Phase 1 | NCT05549804 |
| SNX281 | non-CDN molecule | IV | Alone or + Pembrolizumab | Advanced solid tumors or lymphomas | Phase 1 | NCT04609579 |
| TAK-500 | antibody drug conjugate | IV | Alone or + Pembrolizumab | Advanced/metastatic solid tumors | Phase 1/2 | NCT05070247 |
| SYNB1891 | Engineered bacteria vectors | IT | Alone or + Atezolizumab | Advanced/metastatic solid tumors or lymphomas | Phase 1 | NCT04167137 |
Abbreviations: CDN: cyclic dinucleotide; HNSCC: head and neck squamous cell carcinoma; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; TNBC: triple-negative breast cancer (TNBC); NMIBC: non-muscle invasive bladder cancer; AML: acute myeloid leukemia; HR-MDS: High-risk myelodysplastic syndrome; ICI: immune checkpoint inhibitor; IO: Immuno-oncology; PULSAR: personalized ultra-fractionated stereotactic adaptive radiotherapy; IT: intratumoral; IV: intravenous; IM: intramuscular